JP2008528514A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2008528514A5 JP2008528514A5 JP2007552380A JP2007552380A JP2008528514A5 JP 2008528514 A5 JP2008528514 A5 JP 2008528514A5 JP 2007552380 A JP2007552380 A JP 2007552380A JP 2007552380 A JP2007552380 A JP 2007552380A JP 2008528514 A5 JP2008528514 A5 JP 2008528514A5
- Authority
- JP
- Japan
- Prior art keywords
- disorder
- pharmaceutical composition
- disease
- related disorder
- amino
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 60
- 208000035475 disorder Diseases 0.000 claims 47
- 239000008194 pharmaceutical composition Substances 0.000 claims 31
- 201000010099 disease Diseases 0.000 claims 13
- 150000003839 salts Chemical class 0.000 claims 12
- 239000012453 solvate Substances 0.000 claims 12
- 230000033115 angiogenesis Effects 0.000 claims 7
- 239000002552 dosage form Substances 0.000 claims 7
- 201000001320 Atherosclerosis Diseases 0.000 claims 6
- 208000018565 Hemochromatosis Diseases 0.000 claims 6
- 208000029462 Immunodeficiency disease Diseases 0.000 claims 6
- 208000019693 Lung disease Diseases 0.000 claims 6
- 206010028980 Neoplasm Diseases 0.000 claims 6
- 208000002193 Pain Diseases 0.000 claims 6
- 108060008682 Tumor Necrosis Factor Proteins 0.000 claims 6
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 claims 6
- 208000027418 Wounds and injury Diseases 0.000 claims 6
- 230000002159 abnormal effect Effects 0.000 claims 6
- 239000010425 asbestos Substances 0.000 claims 6
- 201000011510 cancer Diseases 0.000 claims 6
- 208000015114 central nervous system disease Diseases 0.000 claims 6
- 230000006378 damage Effects 0.000 claims 6
- 208000014674 injury Diseases 0.000 claims 6
- 208000002780 macular degeneration Diseases 0.000 claims 6
- 239000000651 prodrug Substances 0.000 claims 6
- 229940002612 prodrug Drugs 0.000 claims 6
- 229910052895 riebeckite Inorganic materials 0.000 claims 6
- 208000017520 skin disease Diseases 0.000 claims 6
- 208000019116 sleep disease Diseases 0.000 claims 6
- 208000020685 sleep-wake disease Diseases 0.000 claims 6
- 208000011580 syndromic disease Diseases 0.000 claims 6
- -1 3-methyl-2,6-dioxo-piperidin-3-yl Chemical group 0.000 claims 5
- 208000030852 Parasitic disease Diseases 0.000 claims 5
- VZTDWPXKIYLLAT-UHFFFAOYSA-N 4-amino-2-(3-methyl-2,6-dioxopiperidin-3-yl)isoindole-1,3-dione Chemical compound O=C1C2=CC=CC(N)=C2C(=O)N1C1(C)CCC(=O)NC1=O VZTDWPXKIYLLAT-UHFFFAOYSA-N 0.000 claims 4
- 238000007911 parenteral administration Methods 0.000 claims 4
- VZTDWPXKIYLLAT-CQSZACIVSA-N 4-amino-2-[(3r)-3-methyl-2,6-dioxopiperidin-3-yl]isoindole-1,3-dione Chemical compound O=C1C2=CC=CC(N)=C2C(=O)N1[C@]1(C)CCC(=O)NC1=O VZTDWPXKIYLLAT-CQSZACIVSA-N 0.000 claims 3
- VZTDWPXKIYLLAT-AWEZNQCLSA-N 4-amino-2-[(3s)-3-methyl-2,6-dioxopiperidin-3-yl]isoindole-1,3-dione Chemical compound O=C1C2=CC=CC(N)=C2C(=O)N1[C@@]1(C)CCC(=O)NC1=O VZTDWPXKIYLLAT-AWEZNQCLSA-N 0.000 claims 3
- 239000013543 active substance Substances 0.000 claims 3
- 239000002775 capsule Substances 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 230000024241 parasitism Effects 0.000 claims 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US64650505P | 2005-01-25 | 2005-01-25 | |
| PCT/US2006/002503 WO2006081251A2 (en) | 2005-01-25 | 2006-01-24 | Methods and compositions using 4-amino-2-(3-methyl-2,6-dioxopiperidin-3-yl)-isoindole-1-3-dione |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2008528514A JP2008528514A (ja) | 2008-07-31 |
| JP2008528514A5 true JP2008528514A5 (enExample) | 2009-07-16 |
Family
ID=36609267
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2007552380A Abandoned JP2008528514A (ja) | 2005-01-25 | 2006-01-24 | ４−アミノ−２−（３−メチル−２，６−ジオキソピペリジン−３−イル）−イソインドール−１，３−ジオンを使用する方法及び組成物 |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US20060205787A1 (enExample) |
| EP (1) | EP1848433A2 (enExample) |
| JP (1) | JP2008528514A (enExample) |
| KR (1) | KR20070099031A (enExample) |
| CN (1) | CN101141960A (enExample) |
| AR (1) | AR052196A1 (enExample) |
| AU (1) | AU2006208201A1 (enExample) |
| BR (1) | BRPI0607239A2 (enExample) |
| CA (1) | CA2595711A1 (enExample) |
| IL (1) | IL184821A0 (enExample) |
| MX (1) | MX2007008903A (enExample) |
| WO (1) | WO2006081251A2 (enExample) |
| ZA (1) | ZA200707010B (enExample) |
Families Citing this family (62)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2005222934B2 (en) * | 2004-03-12 | 2010-06-17 | Entremed, Inc. | Antiangiogenic agents |
| US20070004689A1 (en) * | 2004-03-12 | 2007-01-04 | Agoston Gregory E | Antiangiogenic agents |
| WO2007059111A2 (en) * | 2005-11-14 | 2007-05-24 | Entremed, Inc. | Anti-angiogenic activity of 2-methoxyestradiol in combination with anti-cancer agents |
| US20070253960A1 (en) * | 2006-04-28 | 2007-11-01 | Josee Roy | Pharmaceutical removal of vascular extensions from a degenerating disc |
| WO2008094665A1 (en) * | 2007-01-31 | 2008-08-07 | Entremed, Inc. | Method of treating amyloidosis mediated diseases |
| US7579464B2 (en) * | 2007-05-25 | 2009-08-25 | Hoffmann-La Roche Inc. | Process for preparation of enantiomerically pure compounds |
| CA2710196A1 (en) | 2007-12-20 | 2009-07-09 | Celgene Corporation | Use of micro-rna as a biomarker of immunomodulatory drug activity |
| WO2009105256A2 (en) * | 2008-02-20 | 2009-08-27 | Celgene Corporation | Method of treating cancer by administering an immunomodulatory compound in combination with a cd40 antibody or cd40 ligand |
| CA2725342C (en) | 2008-05-27 | 2024-02-20 | Intra-Cellular Therapies, Inc. | Substituted heterocycle fused gamma-carbolines for sleep disorders and other disorders |
| CA3110964A1 (en) | 2009-03-25 | 2010-09-30 | Xiaokui Zhang | Preventing a symptom of graft-versus-host disease using human placenta-derived intermediate natural killer cells |
| US20120134969A1 (en) | 2009-05-25 | 2012-05-31 | Hiroshi Handa | Pharmaceutical composition containing nuclear factor involved in proliferation and differentiation of central neuronal cells |
| WO2011069608A1 (en) * | 2009-12-09 | 2011-06-16 | Ratiopharm Gmbh | S-lenalidomide, polymorphic forms thereof and blend comprising s- und r-lenalidomide |
| MX337566B (es) | 2010-01-05 | 2016-03-10 | Celgene Corp | Combinación de un compuesto inmunomodulador y una artemisinina o un derivado de ésta para tratar cáncer. |
| EP2699909A1 (en) | 2011-04-18 | 2014-02-26 | Celgene Corporation | Biomarkers for the treatment of multiple myeloma |
| WO2012149299A2 (en) | 2011-04-29 | 2012-11-01 | Celgene Corporaiton | Methods for the treatment of cancer and inflammatory diseases using cereblon as a predictor |
| ES2872967T3 (es) | 2012-06-29 | 2021-11-03 | Celgene Corp | Métodos para determinar la eficacia de fármacos usando IKZF3 (AIOLOS) |
| US9587281B2 (en) | 2012-08-14 | 2017-03-07 | Celgene Corporation | Cereblon isoforms and their use as biomarkers for therapeutic treatment |
| WO2014107622A1 (en) | 2013-01-07 | 2014-07-10 | University Of Southern California | Deoxyuridine triphosphatase inhibitors |
| WO2014145192A1 (en) | 2013-03-15 | 2014-09-18 | Intra-Cellular Therapies, Inc. | Organic compounds |
| US20150031697A1 (en) * | 2013-07-26 | 2015-01-29 | Wisconsin Alumni Research Foundation | Method for preventing ultraviolet radiation-induced cutaneous damage and development of squamous cell carcinomas |
| CN104557858B (zh) * | 2013-10-29 | 2018-06-01 | 上海医药工业研究院 | 一种泊利度胺的制备方法 |
| KR102967223B1 (ko) | 2013-12-03 | 2026-05-19 | 인트라-셀룰라 써래피스, 인코퍼레이티드. | 신규한 방법 |
| WO2015103489A1 (en) | 2014-01-03 | 2015-07-09 | University Of Southern California | Heteroatom containing deoxyuridine triphosphatase inhibitors |
| KR20220054908A (ko) | 2014-04-04 | 2022-05-03 | 인트라-셀룰라 써래피스, 인코퍼레이티드. | 유기 화합물 |
| ES2843973T3 (es) | 2014-06-27 | 2021-07-21 | Celgene Corp | Composiciones y métodos para inducir cambios conformacionales en cereblon y otras ubiquitina ligasas E3 |
| WO2016073184A1 (en) | 2014-11-04 | 2016-05-12 | Dana Farber Cancer Institute, Inc. | Compositions and methods for treating multiple myeloma |
| US10577321B2 (en) | 2015-07-08 | 2020-03-03 | University Of Southern California | Deoxyuridine triphosphatase inhibitors |
| WO2017006271A1 (en) | 2015-07-08 | 2017-01-12 | University Of Southern California | Deoxyuridine triphosphatase inhibitors containing amino sulfonyl linkage |
| DK3319939T3 (da) | 2015-07-08 | 2025-02-24 | Cv6 Therapeutics Ni Ltd | Hydantoin indeholdende deoxyuridintriphosphatase-inhibitorer |
| US10544105B2 (en) | 2015-07-08 | 2020-01-28 | Cv6 Therapeutics (Ni) Limited | Deoxyuridine triphosphatase inhibitors containing cyclopropano linkage |
| US10830762B2 (en) | 2015-12-28 | 2020-11-10 | Celgene Corporation | Compositions and methods for inducing conformational changes in cereblon and other E3 ubiquitin ligases |
| RU2743513C2 (ru) | 2016-01-26 | 2021-02-19 | Интра-Селлулар Терапиз, Инк. | Органические соединения |
| IL281050B2 (en) | 2016-03-25 | 2023-04-01 | Intra Cellular Therapies Inc | A controlled or delayed release pharmaceutical preparation containing a deuterated compound |
| WO2017172784A1 (en) | 2016-03-28 | 2017-10-05 | Intra-Cellular Therapies, Inc. | Novel salts and crystals |
| WO2017172811A1 (en) | 2016-03-28 | 2017-10-05 | Intra-Cellular Therapies, Inc. | Novel co-crystals |
| US10682354B2 (en) | 2016-03-28 | 2020-06-16 | Intra-Cellular Therapies, Inc. | Compositions and methods |
| JP7013454B2 (ja) | 2016-10-12 | 2022-02-15 | イントラ－セルラー・セラピーズ・インコーポレイテッド | アモルファス固体分散体 |
| US11174271B2 (en) | 2016-11-23 | 2021-11-16 | Cv6 Therapeutics (Ni) Limited | 6-membered uracil isosteres |
| US11014924B2 (en) | 2016-11-23 | 2021-05-25 | Cv6 Therapeutics (Ni) Limited | Hydantoin containing deoxyuridine triphosphatase inhibitors |
| WO2018098209A1 (en) | 2016-11-23 | 2018-05-31 | Cv6 Therapeutics (Ni) Limited | Amino sulfonyl compounds |
| US10858344B2 (en) | 2016-11-23 | 2020-12-08 | Cv6 Therapeutics (Ni) Limited | Hydantoin containing deoxyuridine triphosphatase inhibitors |
| US10829457B2 (en) | 2016-11-23 | 2020-11-10 | Cv6 Therapeutics (Ni) Limited | Nitrogen ring linked deoxyuridine triphosphatase inhibitors |
| WO2018095377A1 (zh) * | 2016-11-24 | 2018-05-31 | 天津和美生物技术有限公司 | 哌啶-2,6-二酮衍生物以及溃疡性结肠炎的治疗 |
| WO2018126140A1 (en) | 2016-12-29 | 2018-07-05 | Intra-Cellular Therapies, Inc. | Organic compounds |
| CN106806366B (zh) * | 2016-12-29 | 2020-02-11 | 兰州大学 | 一种异吲哚-1，3-二酮类化合物的新用途 |
| EP3562484B1 (en) | 2016-12-29 | 2021-08-25 | Intra-Cellular Therapies, Inc. | Pyrido[3',4':4,5]pyrrolo[1,2,3-de]quinoxaline derivatives useful in the treatment of cns disorders |
| US11247984B2 (en) | 2017-01-05 | 2022-02-15 | Cv6 Therapeutics (Ni) Limited | Uracil containing compounds |
| EP3600325A4 (en) | 2017-03-24 | 2021-01-06 | Intra-Cellular Therapies, Inc. | UNIQUE COMPOSITIONS AND PROCESSES |
| JP7224333B2 (ja) | 2017-07-26 | 2023-02-17 | イントラ－セルラー・セラピーズ・インコーポレイテッド | 有機化合物 |
| WO2019023062A1 (en) | 2017-07-26 | 2019-01-31 | Intra-Cellular Therapies, Inc. | ORGANIC COMPOUNDS |
| BR112020017053A2 (pt) | 2018-02-21 | 2020-12-15 | Celgene Corporation | Anticorpos que se ligam ao bcma e usos dos mesmos |
| SMT202600133T1 (it) | 2018-03-23 | 2026-05-12 | Intra Cellular Therapies Inc | Composti organici |
| AU2019240226B2 (en) | 2018-03-23 | 2024-11-28 | Intra-Cellular Therapies, Inc. | Organic compounds |
| BR112020024885A2 (pt) | 2018-06-06 | 2021-03-09 | Intra-Cellular Therapies, Inc. | Novos sais e cristais |
| EP3801527B1 (en) | 2018-06-08 | 2025-02-19 | Intra-Cellular Therapies, Inc. | Fused gamma-carbolines for acute treatment of anxiety or depression |
| US12144808B2 (en) | 2018-08-29 | 2024-11-19 | Intra-Cellular Therapies, Inc. | Compositions and methods |
| WO2020047408A1 (en) | 2018-08-31 | 2020-03-05 | Intra-Cellular Therapies, Inc. | Novel methods |
| AU2019328528B2 (en) | 2018-08-31 | 2025-01-23 | Intra-Cellular Therapies, Inc. | Novel methods |
| EP4134101A1 (en) | 2019-07-07 | 2023-02-15 | Intra-Cellular Therapies, Inc. | Deuterated lumateperone for the treatment of the bipolar ii disorder |
| CN114885602A (zh) | 2019-10-21 | 2022-08-09 | 新基公司 | 包含(s)-2-(2,6-二氧代哌啶-3-基)-4-((2-氟-4-((3-吗啉代氮杂环丁烷-1-基)甲基)苄基)氨基)异吲哚啉-1,3-二酮的药物组合物及其使用方法 |
| SMT202600194T1 (it) | 2019-10-21 | 2026-05-12 | Celgene Corp | Combinazione di composti di 4-amminoisoindolin-1,3-dione sostituiti e di secondi agenti attivi per l'uso nel trattamento di una condizione maligna ematologica |
| US12414948B2 (en) | 2022-05-18 | 2025-09-16 | Intra-Cellular Therapies, Inc. | Methods |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HU228769B1 (en) * | 1996-07-24 | 2013-05-28 | Celgene Corp | Substituted 2(2,6-dioxopiperidin-3-yl)phthalimides and -1-oxoisoindolines and their use for production of pharmaceutical compositions for mammals to reduce the level of tnf-alpha |
| US6281230B1 (en) * | 1996-07-24 | 2001-08-28 | Celgene Corporation | Isoindolines, method of use, and pharmaceutical compositions |
| US5635517B1 (en) * | 1996-07-24 | 1999-06-29 | Celgene Corp | Method of reducing TNFalpha levels with amino substituted 2-(2,6-dioxopiperidin-3-YL)-1-oxo-and 1,3-dioxoisoindolines |
| US7091353B2 (en) * | 2000-12-27 | 2006-08-15 | Celgene Corporation | Isoindole-imide compounds, compositions, and uses thereof |
-
2006
- 2006-01-24 BR BRPI0607239-9A patent/BRPI0607239A2/pt not_active IP Right Cessation
- 2006-01-24 JP JP2007552380A patent/JP2008528514A/ja not_active Abandoned
- 2006-01-24 ZA ZA200707010A patent/ZA200707010B/xx unknown
- 2006-01-24 WO PCT/US2006/002503 patent/WO2006081251A2/en not_active Ceased
- 2006-01-24 EP EP06719389A patent/EP1848433A2/en not_active Withdrawn
- 2006-01-24 CN CNA2006800081712A patent/CN101141960A/zh active Pending
- 2006-01-24 AR ARP060100261A patent/AR052196A1/es not_active Application Discontinuation
- 2006-01-24 KR KR1020077019386A patent/KR20070099031A/ko not_active Withdrawn
- 2006-01-24 AU AU2006208201A patent/AU2006208201A1/en not_active Abandoned
- 2006-01-24 CA CA002595711A patent/CA2595711A1/en not_active Abandoned
- 2006-01-24 MX MX2007008903A patent/MX2007008903A/es not_active Application Discontinuation
- 2006-01-25 US US11/338,688 patent/US20060205787A1/en not_active Abandoned
-
2007
- 2007-07-24 IL IL184821A patent/IL184821A0/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2018021046A5 (enExample) | ||
| JP2010504973A5 (enExample) | ||
| JP2009506117A5 (enExample) | ||
| EP1957110A4 (en) | METHOD FOR PRODUCING COUGAR DOSAGE FORMS FOR MEDICAL CARE AND PRODUCTS THEREFROM | |
| JP2015528471A5 (enExample) | ||
| AR052196A1 (es) | Metodos y composiciones que utilizan 4-amino-2-(3-metil-2,6- dioxopiperidin-3-il)-isoindol-1,3-diona | |
| MA29875B1 (fr) | Formule de capsules de pirfenidone et excipients pharmacocompatibles | |
| JP2017504611A5 (enExample) | ||
| MX2018008021A (es) | Metodos y composiciones para el tratamiento de trastornos relacionados con convulsiones. | |
| NZ599199A (en) | 4'-o-substituted isoindoline derivatives and compositions comprising and methods of using the same | |
| JP2018537507A5 (enExample) | ||
| RU2016144479A (ru) | Фармацевтические композиции для лечения заболеваний, опосредопосредованных муковисцидозным трансмембранным регулятором проводимости | |
| SG10201407947WA (en) | Compressible-coated pharmaceutical compositions and tablets and methods of manufacture | |
| JP2021152008A5 (enExample) | ||
| JP2004512328A5 (enExample) | ||
| JP2009510171A5 (enExample) | ||
| HRP20150644T1 (hr) | Metoda za lijeäśenje atrijalne fibrilacije | |
| JP2016500063A5 (enExample) | ||
| EP4623993A3 (en) | Formulations of (+)-2-[1-(3-ethoxy-4-methoxy-phenyl)-2-methanesulfonyl-ethyl]-4-acetyl aminoisoindoline-1,3-dione | |
| JP2009511450A5 (enExample) | ||
| HK1206246A1 (en) | Use of high dose laquinimod for treating multiple sclerosis | |
| JP2020529995A5 (enExample) | ||
| AR045289A1 (es) | Forma de dosificacion oral de liberacion controlada que comprende 4-(2-di-n-propilaminoetil) - 2(3h)-indolona (ropi-nirol) y uso de dicha forma de dosificacion para la elaboracion de un medicamento | |
| RU2014141893A (ru) | Применение производной пиразола в лечении острых приступов хронической обструктивной болезни легких | |
| JP2009541409A5 (enExample) |